Confluence Investment Management LLC reduced its position in Natus Medical Inc (NASDAQ:BABY) by 2.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,022,092 shares of the medical equipment provider’s stock after selling 22,069 shares during the period. Confluence Investment Management LLC owned approximately 3.28% of Natus Medical worth $39,044,000 at the end of the most recent quarter.
Several other hedge funds also recently modified their holdings of the company. Pinebridge Investments L.P. raised its stake in Natus Medical by 1.7% during the second quarter. Pinebridge Investments L.P. now owns 4,359 shares of the medical equipment provider’s stock worth $163,000 after acquiring an additional 71 shares during the period. Victory Capital Management Inc. increased its stake in shares of Natus Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after purchasing an additional 560 shares during the period. Sei Investments Co. increased its stake in shares of Natus Medical by 29.7% in the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after purchasing an additional 728 shares during the period. Alliancebernstein L.P. increased its stake in shares of Natus Medical by 2.3% during the second quarter. Alliancebernstein L.P. now owns 53,756 shares of the medical equipment provider’s stock valued at $2,005,000 after acquiring an additional 1,190 shares during the period. Finally, Riverhead Capital Management LLC increased its stake in shares of Natus Medical by 90.9% during the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after acquiring an additional 1,364 shares during the period. 99.87% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts recently commented on BABY shares. BidaskClub cut shares of Natus Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Zacks Investment Research upgraded shares of Natus Medical from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Finally, William Blair downgraded shares of Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $46.50.
In other Natus Medical news, Director William M. Moore sold 5,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $41.01, for a total value of $205,050.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the business’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $42.91, for a total transaction of $542,468.22. Following the completion of the transaction, the vice president now owns 141,414 shares in the company, valued at $6,068,074.74. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.
Natus Medical Inc (BABY) traded down $0.05 during midday trading on Monday, reaching $28.95. 862,700 shares of the company’s stock traded hands, compared to its average volume of 1,200,700. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36. The firm has a market cap of $901.91, a price-to-earnings ratio of -482.50 and a beta of 0.84. Natus Medical Inc has a 52 week low of $28.40 and a 52 week high of $43.60.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.02. The company had revenue of $122.60 million for the quarter, compared to analyst estimates of $122.41 million. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The business’s quarterly revenue was up 34.9% on a year-over-year basis. During the same period last year, the business posted $0.39 EPS. sell-side analysts forecast that Natus Medical Inc will post 1.64 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Natus Medical Inc (NASDAQ:BABY) Shares Sold by Confluence Investment Management LLC” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/15/confluence-investment-management-llc-has-39-04-million-position-in-natus-medical-inc-baby.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.